Hospitalisation course and outcomes of patients who were critically ill with COVID-19 with and without thrombocytopenia and with and without disseminated intravascular coagulation
| Non-thrombocytopenic cohort, n=50 | Thrombocytopenic cohort, n=57 | p-value | No DIC, n=91 | DIC, n=16 | p-value | |
|---|---|---|---|---|---|---|
| Mechanical ventilation, n (%) | 35 (70.0) | 50 (87.7) | 0.043 | 69 (75.8) | 16 (100.0) | 0.061 |
| Blood products, n (%) | 21 (42.0) | 41 (71.9) | 0.003 | 47 (51.6) | 15 (93.8) | 0.004 |
| PLT, n (%) | 0 (0.0) | 13 (22.8) | 0.001 | 6 (6.6) | 7 (43.8) | <0.001 |
| FFP, n (%) | 2 (4.0) | 13 (22.8) | 0.012 | 8 (8.8) | 7 (43.8) | 0.001 |
| Cryo, n (%) | 0 (0.0) | 7 (12.3) | 0.030 | 1 (1.1) | 6 (37.5) | <0.001 |
| ECS, n (%) | 6 (12.0) | 33 (57.9) | <0.001 | 26 (28.6) | 13 (81.2) | <0.001 |
| Bleeding, n (%) | 19 (38.0) | 29 (50.9) | 0.254 | 36 (39.6) | 12 (75.0) | 0.018 |
| Thrombosis, n (%) | 4 (8.0) | 8 (14.0) | 0.496 | 10 (11.0) | 2 (12.5) | 1.000 |
| LOS, days, median (IQR) | 18.00 (7.5–39.5) | 33.00 (12.25–40.75) | 0.050 | 22 (12.00–38.00) | 34 (18.75–39.50) | 0.317 |
| Mortality, n (%) | 16 (32.0) | 32 (56.1) | 0.021 | 39 (42.9) | 9 (56.2) | 0.471 |
Cryo = cryoprecipitates; DIC = disseminated intravascular coagulation; ECS = extracorporeal support; FFP = fresh frozen plasma; IQR = interquartile range; LOS = length of stay (survivors); PLT = platelets.